title: [Adipose tissue inflammation and atherosclerosis].
abstract: Adipose tissue is an endocrine organ secreting more than 30 various adipokines which regulate wide spectrum of metabolic and immune processes. Obesity is associated with development of adipose tissue inflammation. This inflammation is characterized by infiltration with macrophages, alterations of adipokine secretion, development of insulin resistance. All these factors promote atherosclerosis. Inflammation of perivascular adipose tissue is especially important. Adipokines damage vascular endothelium via paracrine pathway. Cytokines released by macrophages as well as changes of adipokine secretion lead to endothelial dysfunction - the first stage of atherogenesis. Besides specific action curative factors used in obesity, metabolic syndrome, and diabetes mellitus also produce anti-inflammatory effect and thus diminish risk factors of cardiovascular diseases, rate of their development, and alleviate manifestations of atherosclerosis. Inflammation of adipose tissue is a connecting link between obesity and atherosclerosis. This review contains an outline of roles of various major adipokines in development of atherosclerosis as well as synopsis of anti-inflammatory and antiatherogenic effects of glytazones , metformin, rimonabant, statins, and of lowering of body weight.
authors.forename: V
authors.initials: V
authors.lastname: Shwarts
mesh_terms: D054392:Adipokines / Q000378:metabolism; D000273:Adipose Tissue / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D050197:Atherosclerosis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D002633:Chemotaxis; D016207:Cytokines / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation; D007333:Insulin Resistance; D008264:Macrophages / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D008687:Metformin / Q000627:therapeutic use; D009765:Obesity; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D000077285:Rimonabant; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D054392:Adipokines; D016207:Cytokines; D007004:Hypoglycemic Agents; D010880:Piperidines; D011720:Pyrazoles; D014662:Vasoconstrictor Agents; D008687:Metformin; D000077285:Rimonabant